Traumatic brain injury (TBI) is the major cause of physical disability and emotional vulnerability.
Following the primary injury of a TBI event, secondary injury follows from neuroinflammation, oxidative stress, and mitochondrial dysfunction. This secondary injury hampers extant mechanisms of neuroprotection and neurorepair, thus delaying and limiting neurobehavioral recovery. Recently, we documented that S-nitrosoglutathione (GSNO) reduces secondary injury, protects the brain, and improves neurological function both in cerebral ischemia reperfusion (IR) injury (Khan et al., 2005 and in TBI (Khan et al., 2009) . We have also observed that GSNO promotes functional recovery in experimental spinal cord injury (SCI) (Chou et al., 2011; Shunmugavel, Khan, Chou, & Singh, 2012) . GSNO is a natural component of the human body (Singh, Wishnok, Keshive, Deen, & Tannenbaum, 1996) , present in the brain and other organs (Kluge, Gutteck-Amsler, Zollinger, & Do, 1997) . It invokes its cellular signaling via S-nitrosylation of target proteins, including NF-jB, STAT3, COX-2, caspase-3, calpains, inducible nitric oxide synthase (iNOS), and endothelial NOS (Jaffrey, ErdjumentBromage, Ferris, Tempst, & Snyder, 2001; Khan et al., 2005 Khan et al., , 2012 Kim, Won, Singh, Sharma, & Singh, 2014) . Exogenous administration of GSNO (Rassaf et al., 2006 ) also protects against cardiac ischemic injury (Konorev, Tarpey, Joseph, Baker, & Kalyanaraman, 1995; Lima et al., 2009) , supporting the therapeutic potential of GSNO. Pharmacological inhibition of GSNO reductase, a GSNO degrading enzyme, has also been shown to improve endothelial functions , indicating a protective role of GSNO in neurovascular dysfunction-related diseases. Studies have also reported that GSNO inhibits platelet activation in humans (Radomski, Rees, Dutra, & Moncada, 1992) and protects both blood-brain barrier (BBB) integrity and epithelial permeability (Khan et al., 2009; Savidge et al., 2007) , indicating GSNO's clinical potential. The effects of GSNO are mediated mainly by the mechanism of S-nitrosylation, and Snitrosylation-based mechanistic ability is not embedded in conventional NO donors, making GSNO a unique candidate for TBI therapy.
However, GSNO's effects on mitochondrial efficiency/quality and redox are less understood.
Like GSNO, caffeic acid phenethyl ester (CAPE) is a potent neuroprotective agent; it improves neurobehavioral function mainly by its antioxidant activity (Tolba, Azab, Khalifa, Abdel-Rahman, & AbdelNaim, 2013). Because redox is implicated in neuroinflammation, neuronal cell death, and functional deficits (Avila et al., 2008; Besson, 2009; Deng-Bryant, Singh, Carrico, & Hall, 2008; Hall, Kupina, & Althaus, 1999; Singh, Sullivan, & Hall, 2007) , we investigated the efficacy of CAPE in TBI. CAPE is a plant-originated potent lipophilic compound (Son & Lewis, 2002; Zheng & Yenari, 2004) and is well-tolerated in humans. It is rapidly absorbed and metabolized by plasmatic esterases to caffeic acid (Celli et al., 2004) , which is also an effective antioxidant and inhibits the activity of inflammatory 5-lipoxygenase (Teixeira et al., 2015) . A post-TBI administration of CAPE shows reduced cortical tissue loss . In another TBI study, CAPE decreased oxidative stress, reduced neuronal loss and protected tissue structure and effects associated with its antioxidant functions (Kerman, Kanter, Coş-kun, Erboga, & Gurel, 2012) . Because the bulk of reactive oxygen species are generated by several metabolic enzymes residing in mitochondria, the efficiency of mitochondrial function is significant to detoxify secondary injury-induced exacerbations following TBI. Recent studies from our Khan, Elango, Ansari, Singh, & Singh, 2007; Singh, Khan, & Singh, 2013) and other laboratories (Lee et al., 2007; Liao, Ou, Huang, & Wang, 2014; Natarajan, Singh, Burke, Grunberger, & Aggarwal, 1996; Tsuda et al., 2012) suggest that CAPE invokes its protective effects mainly by maintaining mitochondrial integrity through the activation of AMPK and downregulation of inflammation via the inhibition of NF-jB. Recently, studies have shown downregulation of inflammation in microglial cells by CAPE via the inhibition of iNOS and COX-2, activation of AMPK, and the induction of HO-1 Tsai et al., 2015) . These findings support the notion that mitochondrial integrity is well protected by CAPE, likely through induction of Nrf2 (Kim et al., 2013) and activation of AMPK (Feng et al., 2008) . Based on improved mitochondrial activity/function and the proven efficacy of CAPE in animal models of TBI (Kerman et al., 2012; Tsuda et al., 2012; Zhao et al., 2012) and stroke (Suuronen, Huuskonen, Pihlaja, Kyrylenko, & Salminen, 2003) , we investigated the efficacy of CAPE alone and tested whether CAPE accelerates the efficacy of GSNO treatment in TBI. Greater efficacy of combination therapy compared with monotherapy in TBI has been discussed recently (Kline, Leary, Radabaugh, Cheng, & Bondi, 2016) .
Animal models of TBI using the focal controlled cortical impact (CCI) technique are recognized as physiologically relevant to TBI in humans (Bondi et al., 2015; Osier & Dixon, 2016) . CCI provides an opportunity to determine both primary as well as secondary injuries and to evaluate functional deficits. We opted for a subacute phase injury (7 days) study over the acute (24-96 hr) and chronic phases (weeks and months) to avoid the contribution of contusion-induced oxidative exacerbations and the stimulation of profound neurorepair processes, respectively. It is recognized that very severe injury involves several pathways, thus making it difficult to delineate specific ones.
Moreover, 75% of TBI patients in the United States are diagnosed as suffering from mild TBI. Therefore, we used a mild/moderate 7-day TBI mouse model as described (Deng, Thompson, Gao, & Hall, 2007; Khan et al., 2016) to investigate whether the combination (GSNO 1 CAPE) therapy shows greater efficacy compared with GSNO or CAPE alone in mitigating multimechanistic pathology of TBI.
Significance Traumatic brain injury (TBI) is a common and devastating disorder, which causes neurobehavioral deficits in young adults, the elderly, and children. These deficits are often the cause of significant disability and morbidity. TBI patients are also susceptible to dementia, epilepsy, and Alzheimer's disease.
Although several therapeutic compounds provide some degree of improvement by targeting single mechanistic pathways, they are not sufficient in rehabilitating patients with TBI due to the multimechanistic nature of the injury. Therefore, the goal of this study is to determine whether a combination therapy targeting two different mechanistic pathways results in greater efficacy compared to monotherapy following TBI.
| Reagents
GSNO was purchased from World Precision Instruments (Sarasota, FL) and CAPE from Cayman Chemical (Ann Arbor, MI), respectively. All other chemicals and reagents used were purchased from Sigma-Aldrich (St. Louis, MO), unless stated otherwise.
| Animals
Animals were young adult male (3-4 months old) wild type C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME: Stock # 00064) weigh- Animals were euthanized at the endpoints using isoflurane (2.5%). legends. In the GSNO-treated group, the mice were administered freshly prepared GSNO (0.05 mg/kg body weight), which was dissolved in sterile saline (25 ll) and administered iv at 2 hr after CCI. CAPE (5 mg/kg, iv), dissolved in sterile 50% DMSO (25 ml), was also administered at 2 hr after CCI. In the combination group, CAPE (iv) was administered first followed by GSNO (iv) initially at 2 hr after CCI. Daily thereafter, the same dose of CAPE (orally, in 50% DMSO) was administered first followed by the same dose of GSNO (orally in saline). The dose of GSNO treatment was based on our previously reported dose response curve study in a rat and mouse model of TBI (Khan et al., 2009 . The effective dose of CAPE was determined based on the reported dose study from our laboratory using an animal model of cerebral IR (Khan et al., 2007) . The selected dose of both GSNO and CAPE did not alter physiologic parameters, including blood pressure, heart rate, and temperature measured at 1 hr following GSNO or CAPE treatment. Details of the study on physiologic parameters in rats have been published previously (Khan et al., , 2007 .
| Experimental groups, drugs, and dose

| CCI mouse model of TBI
Surgical anesthesia was induced by ketamine (90 mg/kg body weight) and xylazine (10 mg/kg body weight) administered intraperitoneally.
Analgesic buprenorphine was administered pre-emptively to alleviate pain following surgery. The animal was then placed onto a heated pad, with core body temperature maintained at 37.0 6 18C. The animals were secured in a stereotaxic frame and ventilated mechanically. A dab of sterile ophthalmic ointment was placed on each eye to compensate for the decrease in lacrimation during anesthesia. A midline scalp incision was made, and the skin and fascia were reflected to expose the skull. A craniotomy (4 mm) was made in the right hemisphere encompassing bregma and lambda and between the sagittal suture and the coronal ridge with a handheld Michele trephine. Care was taken to avoid injury to the underlying dura mater, which was continuously bathed in sterile normal saline warmed to 37.58C, as described (Fox, Fan, Levasseur, & Faden, 1998) . The resulting bone flap was removed, and the craniotomy was enlarged further with cranial rongeurs. CCI injury was produced in mice as previously described (Fox et al., 1998; Smith et al., 1995; Wang et al., 2013) . Briefly, a cortical contusion was produced on the exposed cortex using a controlled impactor device described by Bilgen (Bilgen, 2005) and used in our laboratory (Shunmugavel et al., 2010) and described in our TBI study (Khan et al., 2009 (Khan et al., , 2016 . Briefly, the impacting shaft was extended, and the impact tip was centered and lowered over the craniotomy site until it touched the dura mater. Then, the rod was retracted and the impact tip was advanced farther to produce a brain injury of moderate severity for mice (tip diameter, 1 mm; cortical contusion depth, 1 mm; impact duration 85 ms; impact velocity, 1.5 m/s). The impact tip was wiped clean with sterile alcohol after each impact and cleaned/disinfected further with cidex after surgery. Core temperature was maintained at 37 6 0.18C with a heating pad during surgery and recorded with a rectal probe. Immediately after injury, the skin incision was closed with nylon sutures, and 2% lidocaine jelly was applied to the lesion site to minimize discomfort. Sham animals underwent the same procedure, excepting the cortical impact. Exclusion criterion included the brains with inconsistent trauma or deeper damage due to heavy inflammation following the CCI.
| Evaluation of motor behavior, sensory function, novel object recognition, and forced swim test
Animals in each group were evaluated for beam walking, foot faults, novel object recognition (NOR), and forced swim test (FST) before and after CCI. All the tasks described below were performed by investigators blinded to the study groups and conditions.
In the motor function test, the mice were examined for fine motor function using a beam-walking task with an elevated narrow beam (80 cm long 3 2.5 cm wide) raised 10 cm above ground level. The time to traverse the beam was recorded and analyzed after three trials (60 s allotted time). The beam test was selected over other motor function tests to detect motor deficits because the test is suitable for aged as well as young rodents. Animals were pretrained for 3 days before CCI. We routinely use this task, as published for IR and TBI studies (Khan et al., 2009 (Khan et al., , 2015a (Khan et al., , 2016 Sakakima et al., 2012) .
The forelimb foot faults or grid walking task, a motor impairment test, was used to determine forelimb movement dysfunction while walking. Mice were placed on elevated horizontal wire grids. Mice place their paws on the wire while moving along the grid. With each step, the paw may fall or slip between wires. These events were recorded as foot faults. The total number of steps that the mouse used to cross the grid was counted, and the total number of foot faults was recorded as described (Zhang et al., 2002) . Mice were trained for 3 days before CCI, and the number of foot faults following CCI at day 7 was recorded.
Nonspatial memory was determined by the NOR test as described . The NOR test evaluates the ability of the animal to recognize a novel object in the environment. The NOR test wooden box (36 cm 3 22 cm 3 18 cm) was located in an isolated and illuminated animal testing room. The animals were allowed to explore the test box for 15 min per day before the actual experiments. The NOR test box was devoid of any object during the habituation trial. The test was performed on day 7 following CCI, as described (Khan et al., 2016) . During session I, two objects, A1 and A2, with identical texture, color, and size were presented to the test animal for 10 min. After a 24 hr delay in the home cage, the mice were again exposed to the same area with one novel object of different texture, color, and size included (A1 and B) for 4 min. Both the objects and the box were cleaned with alcohol and dried after each trial to remove olfactory cues. Latency (% preference for a novel object) was recorded using a video camera. The advantage of the test is that, unlike the Morris water-maze task, it is independent of motor function (Dhawan et al., 2011) .
The FST has been used to measure depressive-like behavior in mice following trauma. The test was performed as previously described (Can et al., 2012) . A cylindrical tank (30 cm height 3 20 cm diameter) made of Plexiglass was used in the study. Water level was maintained 15 cm from the bottom uniformly for all the mice tested. During the test, the mice were unable to touch the bottom of the tank either with their hind limbs or tail. The entire experiment was recorded with a video camera mounted on a tripod. Tests were performed individually in sequence, avoiding the use of dividers between the tanks. The mice were forced to swim for 8 min 24 hr before the actual test. On the day of the test (7th day after CCI), each mouse was given a forced swim period of 6 min. The last 4 min of the total 6 min was used for final calculation. Periods of mobility and immobility were calculated as described by Can et al. (2012) .
| Histology and immunohistochemistry
NeuN immunostaining indicates number of neurons. The degree of neuronal damage (loss of viable neurons) was evaluated by cresyl violet (Nissl) staining. Cellular infiltration and tissue damage were assessed by hematoxylin and eosin (H&E) staining as previously described in a rat TBI brain . Nissl staining highlights important structural features of neurons. Paraffin-embedded brain sections from the formalin-fixed brain tissues, processed at 7 days after CCI, were used to stain with H&E and Nissl, and the staining was performed according to classical histology methods as previously described from our laboratory (Khan et al., , 2015a Sakakima et al., 2012) . Cells that contained Nissl substance were considered to be viable neurons.
Condensed, fragmented staining shows neuronal degeneration.
Paraffin-embedded brain sections (6 mm thick) from the formalinfixed brain tissues, processed at 7 days after CCI, were used to immunostain with NeuN, and the staining was performed using a NeuNspecific antibody, RRID:AB_2298772 (1:250 dilution) from Millipore (Billerica, MA) as described (Liu, Schafer, & McCullough, 2009 ). The percent of NeuN positive area was determined as previously described from our laboratory , and viable neurons from Nissl staining were quantified by manually counting cells as previously described from our and other laboratories (Khan et al., 2015a; Zhu, Bu, Liu, Hu, & Wang, 2014) in the traumatic penumbra area using an Olympus microscope. Histological analysis was performed by an observer blinded to the identity of groups, as previously described from our laboratory (Khan et al., 2015a; Sakakima et al., 2012) .
| Western blot analysis
In the traumatic penumbra area from the ipsilateral injured brain tissue, Western blot was performed using antibodies against PGC-1a (RRID: AB_2268435), Drp1 (RRID:AB_11178938), Fis1(RRID:AB_11204021), Opa1 (RRID:AB_944550), AMPKa1 (RRID:AB_310542), pAMPK (Thr172) (RRID:AB_1977022), MnSOD (RRID:AB_525598), HO-1 (RRID:AB_764541), and b-actin (RRID:AB_303668) as described in our publications (Khan, Dhammu, Matsuda, Singh, & Singh, 2015b; Khan et al., 2012 Khan et al., , 2016 . Detail of antibodies is described in Table 1 . After washing, the membranes were incubated with 1:10,000 diluted horseradish Peroxidase-AffiniPure Goat Anti-Rabbit IgG secondary antibody (RRID:AB_2337938) for 1 hr at room temperature, again washed, reacted with ECL reagent from Amersham Life Science (Pittsbrugh, PA), and subjected to autoradiography. b-actin expression level was used as an internal control for equal protein loading. Protein concentrations were determined using protein assay dye from Bio-Rad Laboratories (Hercules, CA). Blots were scanned for densitometry using an Epson perfection 1200 U scanner, transferred to Adobe Photoshop CS2, and the images were analyzed by NIH Image J software.
| Activation of AMPK by CAPE in mice brain
We determined the expression of activated AMPK and pAMPK (phosphorylated AMPK) in the cortical/striatal brain region from normal control animals. The expression of AMPK substrate acetyl co-A carboxylase (ACC) as pACC and AMPK upstream kinase LKB1 as pLKB1 were determined using specific antibodies to support AMPK activation. Mice were injected iv with 5 mg/kg CAPE in 50% DMSO | 1903 using specific antibodies in cortical brain region using western analysis and densitometry. Detail of antibodies is described in Table 1 .
| Statistical evaluation
Statistical analysis was performed using Graph pad Prism 5.01 software as described (Khan et al., 2015a) . The results are presented as the mean 6 SD. Statistical significance was analyzed by one-way or two-way analysis of variance (ANOVA) with repeated measures with time, and the Bonferroni post hoc test was used for multiple comparisons. Student's ttest was used to compare values between two groups as described in Figure 6 . A p value of less than .05 was considered significant.
| R E SU LTS
3.1 | GSNO or CAPE treatment for 7 days improved motor, nor and FST functions, and combination GSNO and CAPE treatment accelerated nor and FST functions following TBI Using GSNO or CAPE, we tested the hypothesis that TBI-mediated compromised neurobehavioral functions, especially motor coordination and balance, cognition and depressive-like behaviors are improved following TBI. We also determined whether the combination of GSNO 1 CAPE accelerated functional recovery. GSNO or CAPE treatment significantly improved beam walking latency (Figure 1a 3.2 | GSNO or CAPE treatment for 7 days reduced neuron loss/neurodegeneration and protected brain tissue integrity, and the combination treatment showed additive effects following TBI The therapeutic efficacy of GSNO, CAPE, and CAPE 1 GSNO was determined in reducing neuronal loss, increasing number of viable neurons, and the integrity of brain tissue. Neuronal loss and neurodegeneration were evaluated by neuronal nuclear protein (NeuN, Figure 2a) immunostaining and cresyl violet (Nissl, Figure 2b (Figure 2c ).
3.3 | GSNO or CAPE treatment for 7 days reduced the expression of mitochondrial fission mediators (Drp1, Fis1) and increased the expression of the mitochondrial fusion mediator (Opa1), and the combination treatment showed synergistic effects on Drp1 following TBI Because mitochondrial function is essentially associated with neuroprotection and functional recovery, we investigated the impact of GSNO, CAPE, and GSNO 1 CAPE on mitochondrial integrity/function. Mitochondrial quality control is regulated by the antagonistic forces of fission and fusion. Therefore, we determined the expression of fission Unlike the effect on the expression of Drp1, the combination group showed no greater effects on Opa1 (Figure 3a,b) .
3.4 | GSNO or CAPE treatment for 7 days increased expression of mitochondrial biogenesis factor PGC1a and antioxidant enzymes HO-1 and MnSOD, and combination treatment showed additive effects following TBI Mitochondrial function (PGC1a, MnSOD) and antioxidant activity (HO-1) were determined using Western blot analysis ( Figure 4a ) and densitometry ( Figure 4b ). The expression PGC1a was decreased whereas HO-1 and MnSOD increased in the TBI group. GSNO treatment had no effect on the expression levels of PGC1a ( Figure 4a 
| D ISC USSION
Both GSNO and CAPE have an acceptable mechanistic rationale, good safety record, and favorable pharmacokinetic profile. We designed this study to investigate, first, the efficacy of these neuroprotective compounds alone and then extended the study to examine the greater efficacy, if any, of GSNO 1 CAPE combination therapy. Combination therapies have been documented better for optimal neurobehavioral and cognitive recovery after experimental TBI (Kline et al., 2016) . Our previous studies showing the efficacy of GSNO in a rat/mouse model of TBI (Khan et al., 2009 (Khan et al., , 2016 and the neuroprotective effect of CAPE in a rat model of cerebral IR (Khan et al., 2007) provided a rationale to combine them for potentially greater efficacy and accelerated functional recovery.
As expected, all three treated groups showed significant improvements with respect to improved beam walk latency ( Figure 1a ) and FIG URE 2 Effect of GSNO, CAPE, and combination GSNO 1 CAPE for 7 days on neuronal survival/degeneration and tissue histology. Photomicrographs of DAB staining of immunoreactivity and percentage of area of NeuN (a, a1), neuronal viability staining, viable neuron count (Nissl; b, b1), and brain tissue H&E staining (c) showing enhanced inflammatory infiltration in the traumatic penumbra region of TBI group. Data are presented as mean 6 SD (n 5 4). ***p < .001 vs. Sham, 111p < .001 and 11p < .01 vs. TBI, #p < .05 and ##p < .01 vs. GSNO, $p < .05 vs. CAPE foot faults (Figure 1b) . However, the anticipated greater balance and coordination recovery in the combination group compared with the GSNO or the CAPE alone group was not observed (Figure 1a,b) . The beam walk test evaluates balance and coordination of movement, and it is sensitive to degree of injury and therapeutic manipulation (Fujimoto et al., 2004) . Normalization of beam walk and fault functions at 7th day after TBI (Figure 1a ,b) in all groups may be due to the mild/ moderate degree of injury in our model. In contrast to motor function, nonspatial memory (evaluated by NOR test, Figure 1c ) and depressivelike behavior (evaluated by FST, Figure 1d ) were significantly improved in the combination (GSNO 1 CAPE) group compared with the GSNO or the CAPE alone group (Figure 1c,d) . Although depressive-like behavior (FST) is a significant consequence and common to mild, moderate, and severe TBI (Washington et al., 2012) , only one study has investigated its pharmacological regulation in TBI via an inhibition of the 5-lipoxygenase-induced oxidative stress pathway (Higashi et al., 2014) .
Both CAPE (Feng et al., 2008; Khan et al., 2007) and GSNO (Chiueh & Rauhala, 1999; Khan et al., 2011; Rauhala, Lin, & Chiueh, 1998 ) are potent antioxidants. Thus, the greatly improved FST in the combination group compared with the GSNO or the CAPE alone indicates the potential of the combination therapy to ameliorate depression and emotion-associated deficits following TBI. Cognitive deficit is another major issue associated with TBI. We used a NOR test to evaluate cognition as described . The advantage of this test is that it can be performed well irrespective of the age of mice or rats.
Unlike the Morris water-maze task, its outcomes are independent of motor function (Dhawan et al., 2011) . Like FST function (Figure 1d ), NOR function was also significantly improved in the combination group compared with the GSNO or the CAPE group alone. These results clearly support the notion that the combination treatment is more effective to reduce cognitive and emotional deficits. Because both mitochondrial function and cellular energy metabolism play key roles in neuroprotection and functional recovery, we investigated the effect of GSNO, CAPE, and GSNO 1 CAPE on improving mitochondrial function and cellular energy metabolism.
Treated groups had reduced infiltration and improved tissue structure as shown by H&E staining (Figure 2c ). In parallel, they provided significant neuroprotection as evident from a significantly increased with mitochondrial function, we determined the quality and efficiency
Effect of GSNO, CAPE, and combination GSNO 1 CAPE for 7 days on expression of Drp1, Fis1, and OPa1. The expression of Drp1, Fis1, and OPa1 was measured in the traumatic penumbra region using western analysis (a) and its densitometry (b). TBI had an increased expression of Drp1 and Fis1 and a decreased expression of Opa1. The levels of both Drp1 and Fis1 were decreased in both GSNO and CAPE groups compared with TBI group. Treatment with GSNO 1 CAPE further decreased the levels of Drp1. All treatment groups also had increased expression of Opa1. Data are presented as mean 6 SD (n 5 4). ***p < .001 vs. Sham, 111p < .001 vs. TBI, ###p < .001 vs. GSNO, $$p < .01 vs. CAPE [Color figure can be viewed at wileyonlinelibrary.com] FIGURE 4 Effect of GSNO, CAPE, and combination GSNO 1 CAPE for 7 days on the expression of PGC1a, HO-1, and MnSOD. The expression of PGC1a, HO-1, and MnSOD was measured in the traumatic penumbra region using western analysis (a) and its densitometry (b). TBI brain had reduced expression of PGC1a, HO-1, and increased expression of MnSOD. All treated groups had increased expression of PGC1a, HO-1, and MnSOD compared with TBI group. However, GSNO 1 CAPE group had increased expression of HO-1 and MnSOD compared with GSNO or CAPE alone. Data are presented as mean 6 SD (n 5 4). (Fischer et al., 2016) , and mitochondrial quality control is regulated by antagonistic fission and fusion, which determine mitochondrial quality, integrity, and functions (Di Pietro et al., 2017) . The fission of mitochondria has been reported to be regulated by AMPK (Wang & Youle, 2016) . Therefore, we determined the expression of fission (Drp1 and In TBI, the NO metabolome is derailed due to oxidative stress (Khan, Khan, Singh, & Singh, 2017; Khan et al., 2016) . After injury, NO released by nitric oxide synthases (NOS) is consumed by superoxide to form peroxynitrite, a highly potent oxidant in biological systems (Pacher, Beckman, & Liaudet, 2007) . In such an environment, the levels of endogenous redox modulator GSNO are depleted, causing activation of calpains and caspases, leading to neuroinflammation, cell death, and functional deficits Corti, Franzini, Scataglini, & Pompella, 2014; Khan et al., 2011 Khan et al., , 2016 . Supplementation of GSNO in a number of neurodegenerative diseases provides neuroprotection and functional recovery (Khan et al., 2005 (Khan et al., , 2016 . These neuroprotective effects of GSNO may be associated with its reported inhibition of the activity of caspase-3 (Khan et al., 2005; Mohr, Zech, Lapetina, & Brune, 1997) as well as calpains Khan et al., 2016) . The same is anticipated in TBI because conventional NO-donors or NO gas itself may immediately be inactivated by Like GSNO, CAPE confers neuroprotection in animal models of TBI (Kerman et al., 2012) and cerebral ischemia/reperfusion (Khan et al., 2007) . It also protects against neonatal brain hypoxic-ischemic
Effect of GSNO, CAPE, and combination GSNO 1 CAPE for 7 days on activation and expression of AMPK. Activation of AMPK (measured as increased levels of AMPK phosphorylation) and expression of total AMPK (AMPKa) were measured in traumatic penumbra region using western analysis (a) and its densitometry (b). While CAPE treatment increased AMPK activation levels, GSNO treatment had no significant effects on AMPK activation. Treatment with GSNO 1 CAPE had synergistic effects. Data are presented as mean 6 SD (n 5 4). ***p < .001 vs. Sham, 111p < .001 vs. TBI, ###p < .001 vs. GSNO, $p < .05 vs. CAPE [Color figure can be viewed at wileyonlinelibrary.com] injury (Wei et al., 2004) . In experimental TBI, it protects BBB . However, the molecular mechanisms underlying CAPEmediated reductions in brain injury and improvements of neurological functions are not clear. Recent studies from our (Singh et al., 2013 ) and other laboratories (Aladag et al., 2006; Cengiz et al., 2007; Fontanilla et al., 2012; Ilhan et al., 2004; Natarajan et al., 1996; Tsai et al., 2006) suggest that CAPE invokes its protective effects mainly by maintaining mitochondrial integrity and activating AMPK. These findings support the notion that CAPE is a suitable agent to be used as a potent antioxidant therapy in TBI. In view of these properties in neurodegenerative animal models, we used CAPE as a therapeutic agent to enhance the efficacy of GSNO by improving redox and mitochondrial structure/ function (Feng et al., 2008) . CAPE is a plant-originated naturally occurring lipophilic antioxidant without any apparent toxicity in humans. In this study, CAPE was found to improve significantly mitochondrial efficiency by regulating the fission/fusion process and increasing antioxidant levels for accelerated recovery in a mouse model of experimental TBI. The treatment also improved cognitive function alone and accelerated recovery when combined with GSNO. In addition to improving the mitochondrial function and reducing the oxidative damage, CAPE likely contributed an additional benefit by activating AMPK. AMPK activation has been documented to ameliorate neurodegeneration and improve neurological functions in several neurodegenerative diseases, including TBI (Tsai et al., 2015) .
To provide evidence that CAPE is a potent AMPK activator, normal animals were treated with CAPE for 2 hr. An increased level of pLKB1, pAMPK, and pACC in brain tissue ( Figure 6 ) indicates that CAPE activates AMPK via LKB1. Several flavonoid-based phytochemicals are reported to activate AMPK. While the exact sequence of molecular events leading to CAPE-mediated activation of AMPK has yet to be clarified, our evidence suggests that CAPE directly activates AMPK ( Figure 6 ). Based on our data and discussions herein, it is clear that combining antioxidant/Nrf2 with AMPK pathway results in greater neuroprotection and accelerated functional recovery. Supporting this notion, a dual AMPK/Nrf2 activator has been reported to ameliorate stroke injury .
| Limitations
The most affected population from TBI is recognized to be young adult males. Therefore, we used young adult males in this study. At the same time, the differential effects of therapeutic compounds such as GSNO are well established (Wu et al., 2007) . Therefore, in follow-up longer time study, the efficacy of GSNO, CAPE, and GSNO 1 CAPE will be investigated using both male and female young adult mice to determine sex-based mechanistic differences and functional recovery, if any.
Our study shows that a combined treatment with GSNO and CAPE mitigates TBI pathology. The combination reduces cognitive and emotional deficits through additive mechanisms, improving mitochondrial efficiency, and stimulating the cellular energy switch AMPK.
Therefore, combination GSNO 1 CAPE treatment represents the focus of our next level research as a promising therapy for human TBI.
